Optimizing PARPi in Ovarian Cancer: Practical Guidance on Current Clinical Management Strategies

Review the latest data and expert guidance on PARP inhibitors to enhance your treatment of ovarian cancer. This comprehensive CME/CE/CPE-certified program features decision support tools, focused commentaries, an expert analysis module, and a downloadable slideset.

Robert L. Coleman, MD
Ursula Matulonis, MD


Have you fully integrated the PARP inhibitors—olaparib, niraparib, and rucaparib—into your clinical practice in ovarian cancer? In this commentary, I discuss the importance of PARP inhibitors in ovarian cancer treatment and review considerations guiding their use.

Ursula Matulonis, MD Released: May 2, 2019

Are you aware of the latest data on PARP inhibitors in ovarian cancer? In this commentary, I will discuss 3 key studies on olaparib, rucaparib, and niraparib in platinum-sensitive recurrent ovarian cancer that were presented at ASCO 2019.

Robert L. Coleman, MD Released: June 24, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by independent educational grants from
Clovis Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?